• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination.比较 Alpha、Delta 或 Omicron SARS-CoV-2 变异株引起的 COVID-19 病例的严重程度及其与疫苗接种的关系。
Enferm Infecc Microbiol Clin (Engl Ed). 2024 Apr;42(4):187-194. doi: 10.1016/j.eimce.2022.11.021. Epub 2023 Feb 1.
2
[Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination].[由阿尔法、德尔塔或奥密克戎 SARS-CoV-2 变体引起的 COVID-19 病例的比较严重程度及其与疫苗接种的关联]
Enferm Infecc Microbiol Clin. 2022 Dec 6. doi: 10.1016/j.eimc.2022.11.003.
3
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
4
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性:一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
5
Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.西班牙纳瓦拉 2022 年 1 月至 3 月,在 SARS-CoV-2 变异株奥密克戎 BA.1 为主的流行期间,接种疫苗的 COVID-19 病例住院和重症疾病风险降低。
Euro Surveill. 2023 Feb;28(5). doi: 10.2807/1560-7917.ES.2023.28.5.2200337.
6
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.丹麦的一项观察性队列研究:感染 SARS-CoV-2 奥密克戎变异株与德尔塔变异株导致住院的风险比较。
Lancet Infect Dis. 2022 Jul;22(7):967-976. doi: 10.1016/S1473-3099(22)00154-2. Epub 2022 Apr 22.
7
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性:前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
8
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.疫苗对 Alpha、Delta 或奥密克戎变异株流行期间 SARS-CoV-2 再感染的有效性:一项丹麦全国性研究。
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.
9
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
10
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.接种加强针后感染 SARS-CoV-2:一项前瞻性、基于社区的病例对照研究中的疾病和症状特征。
J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28.

引用本文的文献

1
Impact of COVID-19 Vaccination on Hospitalization and Mortality: A Comparative Analysis of Clinical Outcomes During the Early Phase of the Pandemic.2019冠状病毒病疫苗接种对住院率和死亡率的影响:大流行早期临床结局的比较分析
Infect Dis Rep. 2025 Jun 27;17(4):74. doi: 10.3390/idr17040074.
2
Feasibility and reliability to assess the motor development of infants exposed to gestational COVID-19 using the Alberta Infant Motor Scale remotely.使用艾伯塔婴儿运动量表远程评估孕期感染新冠病毒的婴儿运动发育的可行性和可靠性。
Mhealth. 2024 Sep 19;10:32. doi: 10.21037/mhealth-24-20. eCollection 2024.
3
Individual risk factors associated with SARS-CoV-2 infection during Alpha variant in high-income countries: a systematic review and meta-analysis.与高收入国家阿尔法变异株期间 SARS-CoV-2 感染相关的个体风险因素:系统评价和荟萃分析。
Front Public Health. 2024 Jul 30;12:1367480. doi: 10.3389/fpubh.2024.1367480. eCollection 2024.
4
Analyzing the worldwide progression of COVID-19 cases and deaths using nonlinear mixed-effects model.运用非线性混合效应模型分析全球 COVID-19 病例和死亡的进展。
PLoS One. 2024 Aug 12;19(8):e0306891. doi: 10.1371/journal.pone.0306891. eCollection 2024.
5
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins.S糖蛋白在基于SARS-CoV-2结构蛋白的mRNA脂质纳米颗粒疫苗中提供免疫原性和保护性免疫方面的主要作用。
Vaccines (Basel). 2024 Apr 2;12(4):379. doi: 10.3390/vaccines12040379.
6
Genital Dysbiosis and Different Systemic Immune Responses Based on the Trimester of Pregnancy in SARS-CoV-2 Infection.基于妊娠 trimester 在 SARS-CoV-2 感染中生殖器微生物群落失调与不同的全身免疫反应
Int J Mol Sci. 2024 Apr 12;25(8):4298. doi: 10.3390/ijms25084298.
7
Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.瑞德西韦单抗治疗COVID-19的安全性和有效性:在韩国进行的4期上市后监测研究。
Infect Dis Ther. 2023 Oct;12(10):2417-2435. doi: 10.1007/s40121-023-00859-1. Epub 2023 Oct 13.
8
Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria.对大加那利岛一组患者中新冠病毒疫苗接种情况及其对新冠疫情进展影响的流行病学研究。
Vacunas. 2023 Jun 23. doi: 10.1016/j.vacun.2023.06.005.
9
Effects of Different Types of Recombinant SARS-CoV-2 Spike Protein on Circulating Monocytes' Structure.不同类型的 SARS-CoV-2 刺突蛋白对循环单核细胞结构的影响。
Int J Mol Sci. 2023 May 27;24(11):9373. doi: 10.3390/ijms24119373.

本文引用的文献

1
Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants.同时传播的严重急性呼吸综合征冠状病毒2变种的住院风险和重症风险比较
J Infect Dis. 2023 Feb 1;227(3):332-338. doi: 10.1093/infdis/jiac385.
2
Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.奥密克戎或德尔塔变异株感染及重症的 COVID-19 疫苗有效性评估。
JAMA Netw Open. 2022 Sep 1;5(9):e2232760. doi: 10.1001/jamanetworkopen.2022.32760.
3
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.苏格兰关注的奥密克戎变异株的严重程度和疫苗加强针预防有症状疾病的效果(EAVE II):一项具有巢式病例对照研究设计的全国队列研究。
Lancet Infect Dis. 2022 Jul;22(7):959-966. doi: 10.1016/S1473-3099(22)00141-4. Epub 2022 Apr 22.
4
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.丹麦的一项观察性队列研究:感染 SARS-CoV-2 奥密克戎变异株与德尔塔变异株导致住院的风险比较。
Lancet Infect Dis. 2022 Jul;22(7):967-976. doi: 10.1016/S1473-3099(22)00154-2. Epub 2022 Apr 22.
5
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022.2021 年 12 月至 2022 年 1 月期间,法国针对奥密克戎和德尔塔症状感染以及严重 COVID-19 结局的疫苗诱导和自然获得性保护。
Euro Surveill. 2022 Apr;27(16). doi: 10.2807/1560-7917.ES.2022.27.16.2200250.
6
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
7
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性:前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
8
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.mRNA 疫苗加强剂对卡塔尔奥密克戎感染的保护效果。
N Engl J Med. 2022 May 12;386(19):1804-1816. doi: 10.1056/NEJMoa2200797. Epub 2022 Mar 9.
9
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
10
Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022.与疫苗接种状态、性别、年龄和合并症相关的 Delta 和奥密克戎变异株导致 COVID-19 重症的风险 - 2021 年 7 月至 2022 年 1 月瑞典南部的监测结果。
Euro Surveill. 2022 Mar;27(9). doi: 10.2807/1560-7917.ES.2022.27.9.2200121.

比较 Alpha、Delta 或 Omicron SARS-CoV-2 变异株引起的 COVID-19 病例的严重程度及其与疫苗接种的关系。

Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination.

机构信息

National Centre of Epidemiology - Institute of Health Carlos III, Madrid, Spain.

Centre for the Coordination of Alerts and Health Emergencies - Ministry of Health, Madrid, Spain.

出版信息

Enferm Infecc Microbiol Clin (Engl Ed). 2024 Apr;42(4):187-194. doi: 10.1016/j.eimce.2022.11.021. Epub 2023 Feb 1.

DOI:10.1016/j.eimce.2022.11.021
PMID:36737369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9890374/
Abstract

BACKGROUND

This study compares the severity of SARS-CoV-2 infections caused by Alpha, Delta or Omicron variants in periods of co-circulation in Spain, and estimates the variant-specific association of vaccination with severe disease.

METHODS

SARS-CoV-2 infections notified to the national epidemiological surveillance network with information on genetic variant and vaccination status were considered cases if they required hospitalisation or controls otherwise. Alpha and Delta were compared during June-July 2021; and Delta and Omicron during December 2021-January 2022. Adjusted odds ratios (aOR) were estimated using logistic regression, comparing variant and vaccination status between cases and controls.

RESULTS

We included 5,345 Alpha and 11,974 Delta infections in June-July and 5,272 Delta and 10,578 Omicron in December-January. Unvaccinated cases of Alpha (aOR: 0.57; 95% CI: 0.46-0.69) or Omicron (0.28; 0.21-0.36) had lower probability of hospitalisation vs. Delta. Complete vaccination reduced hospitalisation, similarly for Alpha (0.16; 0.13-0.21) and Delta (June-July: 0.16; 0.14-0.19; December-January: 0.36; 0.30-0.44) but lower from Omicron (0.63; 0.53-0.75) and individuals aged 65+ years.

CONCLUSION

Results indicate higher intrinsic severity of the Delta variant, compared with Alpha or Omicron, with smaller differences among vaccinated individuals. Nevertheless, vaccination was associated to reduced hospitalisation in all groups.

摘要

背景

本研究比较了 Alpha、Delta 或 Omicron 变异株在西班牙共同流行期间引起的 SARS-CoV-2 感染的严重程度,并估计了疫苗接种对严重疾病的变异特异性关联。

方法

将具有遗传变异和疫苗接种状态信息的国家流行病学监测网络报告的 SARS-CoV-2 感染病例视为需要住院治疗的病例,否则为对照。在 2021 年 6 月至 7 月期间比较 Alpha 和 Delta;在 2021 年 12 月至 2022 年 1 月期间比较 Delta 和 Omicron。使用逻辑回归比较病例和对照之间的变异和疫苗接种状态,估计调整后的优势比(aOR)。

结果

我们纳入了 2021 年 6 月至 7 月期间的 5345 例 Alpha 感染和 11974 例 Delta 感染,以及 2021 年 12 月至 2022 年 1 月期间的 5272 例 Delta 感染和 10578 例 Omicron 感染。未接种疫苗的 Alpha(aOR:0.57;95%CI:0.46-0.69)或 Omicron(0.28;0.21-0.36)感染者住院的可能性较低。完全接种疫苗同样降低了 Alpha(0.16;0.13-0.21)和 Delta(6 月至 7 月:0.16;0.14-0.19;12 月至 1 月:0.36;0.30-0.44)的住院风险,但对 Omicron(0.63;0.53-0.75)和 65 岁以上人群的影响较小。

结论

结果表明,与 Alpha 或 Omicron 相比,Delta 变异株具有更高的固有严重程度,而在接种疫苗的个体中差异较小。然而,在所有人群中,疫苗接种都与降低住院率相关。